Form 4: Revolution Medicines CEO Sells Shares After Option Exercise
Insider Transaction Report
Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.
Summary
- Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., executed transactions on November 12, 2025.
- Goldsmith exercised options to acquire 20,000 shares of common stock at an exercise price of $4.09 per share.
- Concurrently, he sold 20,000 shares of common stock at a weighted average price of $65.0705 per share.
- These transactions were conducted under a Rule 10b5-1 trading plan established on December 19, 2024.
- Following these transactions, Goldsmith directly holds 247,863 shares, which includes 193,475 restricted stock units.
- He also indirectly holds 710,898 shares through various trusts.
- Goldsmith retains 157,708 stock options after this exercise.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. While it's an insider sale, it's pre-planned and represents a significant gain for the executive, which can be seen as a positive sign of past performance. The amount sold is also not a massive portion of total holdings.
Positives
- The transaction was executed under a pre-arranged 10b5-1 trading plan, indicating a planned, not reactive, sale.
- The sale price of $65.0705 is significantly higher than the exercise price of $4.09, indicating a substantial gain for the insider.
Negatives
- An insider sale, even if planned, can sometimes be perceived negatively by the market, though the amount is relatively small compared to total holdings.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Mark A. Goldsmith indirectly holds shares through various family trusts: Jonathan Goldsmith Revocable Trust (70,424 shares), Rebecca Goldsmith Revocable Trust (54,498 shares), Rebecca Eve Goldsmith Trust (15,926 shares), and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust (570,050 shares).
Stakeholder Impact
- Shareholders may observe an executive monetizing a portion of their equity, which is a common practice, especially when options are deep in the money. The pre-planned nature via a 10b5-1 plan mitigates concerns about opportunistic selling.
Key Dates
| Date | Description |
|---|---|
| December 15, 2011 | Date of Goldsmith Children's 2011 Irrevocable Education Trust. |
| March 13, 2023 | Date stock options became exercisable. |
| December 19, 2024 | Date Mark A. Goldsmith adopted the 10b5-1 trading plan. |
| November 12, 2025 | Date of stock option exercise and common stock sale transactions. |
| November 14, 2025 | Date the Form 4 was signed. |
| March 12, 2029 | Expiration date of the exercised stock options. |
Recommendation
holdThe filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a signal for investors to buy or sell based solely on this event. The executive still retains a substantial number of shares and options, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an investment thesis.
Keywords
Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Mark A. Goldsmith, 10b5-1 Plan, CEO Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.